Mutual Funds Commodities Research Tax Planning IPO
Google
Web www.equitybulls.com
Union Budget
Budget 2010-2011 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Stock Report

| More
Ipca Laboratories and CDRI enters into agreement to develop Novel Anti Malarial compound

Ipca Laboratories Ltd has announced that Central Drug Research Institute (CDRI) has entered into a collaborative-cum-license agreement with the Company for further development of its compound 99/411, a promising synthetic substitute for drugs based on Artemisinin derived from the plant Artemisia annua.

CDRI, Lucknow is a premier Research Institute of CSIR, Government of India, actively engaged in research areas of national priorities like anti-malarial, tuberculosis and reproductive health along with life style and age related disorders.

Artemisinin based combination therapy has been recommended by WHO for the treatment of P. falciparum malaria. A synthetic substitute of artemisinin will be a major break through in cost effective management of falciparum malaria and multi drug resistant falciparum malaria in clinical practice. The compound under licensing is being developed in oral form to meet the new global challenges of the malaria incidence covering 300-400 million patients every year including the Indian population of around 3 millions.

The gross pharmacological and pre-clinical studies of CDRI compound 99/411 have shown high level of activity after administration via oral route in infected mice and monkeys. The compound is found to be sate in small and large animals without any apparent toxic effects.

The Company is a Mumbai based fast growing fully integrated pharmaceutical Company, leader in anti-malarial drugs in India, producing and exporting wide range of Anti Malarial compounds like Choloroquine, Amodiaquine, Primaquine, Artemether, Arteether and Artesunate and their formulations. The Company has strong thrust on exports. Its exports to over 110 countries accounted for 53% of its turnover. The Company's manufacturing facilities have been approved by regulatory authorities from all over the world. The Company currently spends 4% of its turnover on Research & Development and with this collaborative efforts, the Company is now further expanding its collaborative new Drug Development activities.

Source: Equity Bulls

Posted On: 8/27/2007 12:25:46 AM

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Manugraph India Board to Consider Dividend for 2009-10
BPCL Q1 loss widens to Rs 1718.1 crores
India Infoline Q1 consolidated PAT at Rs 43.14 crores
Shipping Corporation of India Q1 net profit jumps to Rs 191.49 crores
ABB Q2 net profit down to Rs 38.31 crores
REI Agro Q1 net profit higher at Rs 61.59 crores
Indian Hotels Q1 PAT slips to Rs 3.33 crores
Vedant Hotels Board to consider Dividend for 2009-10
Aditya Birla Nuvo Q1 net profit at Rs 148.87 crores
Divis Laboratories to declare Q1 results on Aug 12, 2010
Lupin Fixes Record Date for 5:1 Stock Split
Jai Corp to announce Q1 results on Aug 10, 2010
Hindustan Constrcution Q1 net profit jumps to Rs 28.31 crores
Hindustan Construction Board approves 1:1 Bonus Issue
Tulip Telecom partners Qualcomm for Broadband Wireless Venture
GNFC to consider transfer of telecom business on July 31, 2010
Bihar Tubes Board declares interim dividend of Rs 1 for 2010-11
Alok Industries Board recommends Dividend of Rs 0.25
NR Agarwal Industries Board recommends Dividend of Rs 1.80 for 2009-10
Reliance Media denies acquisition of Inox Leisure
TAK Machinery Board recommends Dividend of 20% for 2009-10
Procter & Gamble to announce FY 2010 results on Aug 18, 2010
NTPC commissions Unit 6 of 490 MW Dadri Project
Electronic Payments fuel the growth for RS Software
Hester Biosciences Signs MOU for setting up an Animal Biological manufacturing unit in Nepal
Glenmark Generics receives tentative approval from the USFDA for Riluzole 50 mg tablets
Sun Pharmaceutical Industries gets favorable verdict on Gemzar Patent
Pioneer Embroideries to consider quarterly results on Aug 11, 2010
AVT Natural Products Board recommends Dividend of Rs 3 for 2009-10
VB Desai Financial Services denies dividend, rights issue proposal
Gujarat State Petronet Q1 net profit higher at Rs 105.09 crores
Balmer Lawrie & Company Board recommends Dividend of Rs 23 for 2009-10
Balaji Amines Board approves 5:1 stock split
Kalpataru Power Board approves Sub-division
Sandur Manganese to set up special alloy steel plant
Competent Auto to consider restructuring on Aug 05, 2010
Petronet LNG Q1 net profit up at Rs 111.37 crores
Federal Bank Q1 profit down to Rs 131.86 crores
Hero Honda Q1 net profit drops to Rs 491.69 crores
Siemens Q3 net profit slips to Rs 156.12 crores
ONGC Q1 PAT down to Rs 3661.14 crores
GHCL Board recommends Dividend of Rs 2 for 2009-10
Central Bank of India Board approves Rights Issue
Central Bank of India Q1 net profit higher at Rs 336.81 crores
Arex Industries Board recommends Final Dividend of 9% for 2009-10
D B Realty assigned CARE A- Credit Rating
SE Investments Sanctioned Credit Facility of Rs.750 Million
Asian Granito Board recommends Dividend of Rs 1 for 2009-10
Tata Teleservices Q1 net profit at Rs 55.78 crores
GRM Overseas Board to consider Dividend for 2009-10


  

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2010